Amarin Corporation plc (AMRN)
After hours:
| Previous close | 0.7912 |
| Open | 0.7800 |
| Bid | 0.7933 x 100 |
| Ask | 0.7979 x 300 |
| Day's range | 0.7725 - 0.8179 |
| 52-week range | 0.6300 - 1.3700 |
| Volume | |
| Avg. volume | 1,483,108 |
| Market cap | 327.175M |
| Beta (5Y monthly) | 1.96 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Portugal
-- Portuguese Ministry of Health approves VAZKEPA® (icosapent ethyl) for national reimbursement to reduce the risk of cardiovascular (CV) events in patients with established cardiovascular disease (CVD)1 -- -- Approval marks eighth national reimbursement of VAZKEPA® in Europe -- DUBLIN, Ireland and BRIDGEWATER, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announces that the Portuguese Ministry of Health has approved VAZKEPA® (icosapent ethyl) for national re
- GlobeNewswire
Amarin to Report Second Quarter 2024 Financial Results and Host Conference Call on July 31, 2024
DUBLIN and BRIDGEWATER, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Aaron Berg, President & CEO, and members of Amarin’s senior management team to discuss its second quarter 2024 results followed by Q&A on Wednesday, July 31st, 2024, at 8:00 a.m. ET. The conference call with management will follow the release of the Company’s second quarter 2024 financial results in the pre-market hours on July 31st. To enh
- GlobeNewswire
Amarin Partner EddingPharm Receives Regulatory Approval for VASCEPA® (Icosapent Ethyl) in Mainland China for Cardiovascular Risk Reduction (CVRR)
-- VASCEPA Approved by the National Medical Products Administration (NMPA) To Reduce the Risk of Cardiovascular Events as an Adjunct to Statin Therapy in Adult Patients with Elevated Triglyceride (TG) Levels (≥150 mg/dL) and Other High-Risk Characteristics as Studied in REDUCE-IT -- -- EddingPharm Now Working to Prepare for National Reimbursement and Drug Listing (NRDL) and Enhance the Commercial Launch of VASCEPA Across Mainland China -- DUBLIN and BRIDGEWATER, N.J., July 08, 2024 (GLOBE NEWSWI
